Elvucitabine
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 4-Amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 181785-84-2  |
| ATC code | None |
| PubChem | CID 469717 |
| UNII | M09BUF90C0 |
| ChEMBL | CHEMBL38700  |
| NIAID ChemDB | 060327 |
| Chemical data | |
| Formula | C9H10FN3O3 |
| Mol. mass | 227.19 g/mol |
 (what is this?) (verify) |
|
Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV.
Currently, it is in Phase II clinical trials.[1]
[edit] References
- ^ "AIDSmeds.com - Elvucitabine". http://www.aidsmeds.com/archive/elvucitabine_1592.shtml. Retrieved 2008-03-21.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
